SGM
SYRE icon

Seven Grand Managers’s Spyre Therapeutics SYRE Stock Holding History

Seven Grand Managers’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20M Buy
225,000
+125,000
+125% +$9.12M 0.8% 28
2026
Q1 		$5.04M Hold
100,000
– – 0.34% 73
2025
Q4 		$3.28M Buy
+100,000
New +$2.61M 0.25% 89

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Seven Grand Managers's SYRE Position: Q2 2026 in Review

Seven Grand Managers increased its Spyre Therapeutics (SYRE) stake by 125% in Q2 2026, buying an estimated $9.12M and bringing the position to 225,000 shares worth $20M. The position accounts for 0.8% of the portfolio, ranked #28.

Seven Grand Managers first reported a position in SYRE in Q4 2025 and has held it in 3 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Seven Grand Managers held 225,000 shares of Spyre Therapeutics worth $20M as of Q2 2026.
  • Seven Grand Managers bought 125,000 Spyre Therapeutics shares in Q2 2026, an estimated $9.12M.
  • Spyre Therapeutics made up 0.8% of Seven Grand Managers's portfolio in Q2 2026, its #28 holding.
  • Seven Grand Managers first reported a position in Spyre Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Seven Grand Managers's 13F filing for Q2 2026, filed 14 Aug 2026.